These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 30615313)

  • 41. The 5T2MM murine model of multiple myeloma: maintenance and analysis.
    Vanderkerken K; Asosingh K; Willems A; De Raeve H; Couck P; Gorus F; Croucher P; Van Camp B
    Methods Mol Med; 2005; 113():191-205. PubMed ID: 15968104
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells.
    Yata K; Yaccoby S
    Leukemia; 2004 Nov; 18(11):1891-7. PubMed ID: 15385929
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma.
    Boylan KL; Gosse MA; Staggs SE; Janz S; Grindle S; Kansas GS; Van Ness BG
    Cancer Res; 2007 May; 67(9):4069-78. PubMed ID: 17483317
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The use of animal models in multiple myeloma.
    Libouban H
    Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma.
    Alici E; Konstantinidis KV; Aints A; Dilber MS; Abedi-Valugerdi M
    Exp Hematol; 2004 Nov; 32(11):1064-72. PubMed ID: 15539084
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of bortezomib on bone disease in multiple myeloma.
    Drake MT; Rajkumar SV
    Am J Hematol; 2009 Jan; 84(1):1-2. PubMed ID: 19030185
    [No Abstract]   [Full Text] [Related]  

  • 47. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models.
    Mittelman M; Neumann D; Peled A; Kanter P; Haran-Ghera N
    Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5181-6. PubMed ID: 11309490
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease.
    Nyman JS; Merkel AR; Uppuganti S; Nayak B; Rowland B; Makowski AJ; Oyajobi BO; Sterling JA
    Bone; 2016 Oct; 91():81-91. PubMed ID: 27423464
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies.
    Mittelman M; Zeidman A; Kanter P; Katz O; Oster H; Rund D; Neumann D
    Eur J Haematol; 2004 Mar; 72(3):155-65. PubMed ID: 14962233
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IL-6 polymorphism, anti-IL-6 therapy and animal models of multiple myeloma.
    Jeffery R; Mitchison NA
    Cytokine; 2001 Nov; 16(3):87. PubMed ID: 11741346
    [No Abstract]   [Full Text] [Related]  

  • 52. [Protective immunity against lymphoma and myeloma in mice with an anti-idiotypic DNA base vaccine].
    Jeanteur P
    Bull Cancer; 1998 Dec; 85(12):990-1. PubMed ID: 9988556
    [No Abstract]   [Full Text] [Related]  

  • 53. Dickkopf-1: a suitable target for the management of myeloma bone disease.
    Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
    Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system.
    Huang SY; Tien HF; Su FH; Hsu SM
    Am J Pathol; 2004 Feb; 164(2):747-56. PubMed ID: 14742278
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.
    Shay G; Tauro M; Loiodice F; Tortorella P; Sullivan DM; Hazlehurst LA; Lynch CC
    Oncotarget; 2017 Jun; 8(26):41827-41840. PubMed ID: 28611279
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Animal models of multiple myeloma and their utility in drug discovery.
    Campbell RA; Berenson JR
    Curr Protoc Pharmacol; 2008 Mar; Chapter 14():Unit 14.9. PubMed ID: 22294221
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade.
    Hallett WH; Jing W; Drobyski WR; Johnson BD
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1133-45. PubMed ID: 21536144
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Myeloma mouse models].
    Nihon Rinsho; 2016 Jul; 74 Suppl 5():92-5. PubMed ID: 30615313
    [No Abstract]   [Full Text] [Related]  

  • 59. [Experimental animal models of multiple myeloma].
    Miyakawa Y
    Nihon Rinsho; 2007 Dec; 65(12):2211-7. PubMed ID: 18069262
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Establishment of multiple myeloma mouse models expressing brain derived neurotrophic factor].
    Wang YD; Hu Y; Zhang L; Huang J; Sun CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):967-72. PubMed ID: 17956671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.